Occasionally, A Health Care Story Leaves Me Speechless (Well, Almost)

As long-time HealthBeat readers know, I have some reservations about hospitals plunging huge sums into plush hotel-like amenities—spas, gourmet food, marble lobbies, mahogany-paneled doctors’ lounges  . . ..  See “Who Will Pay for the Waterfalls?”

I tend to think that hospitals should plow any extra money into programs that will protect patients: infection control, electronic medical records that would prevent medication mix-ups, and so on.

But patients can’t see these improvements. And in competitive urban and suburban markets (where, typically, too many hospitals are vying for well-insured patients) hospital CEOs know that the cosmetic improvements appeal to upscale, well-insured patients.

Continue reading

October 27: Money-Driven Medicine National “Watch-In” Begins With Screening at the U.S. Capitol—Watch the Film At Home—Free Streaming Video Online

Money-Driven Medicine, the film produced by Academy-Award winning filmmaker, Alex Gibney (Taxi to the Dark Side; Enron: The Smartest Guys in the Room), directed by Andy Fredericks, and based on my book (Money-Driven Medicine: The Real Reason Health Care Costs So Much) , will be screened at the U.S. Capitol in Washington DC on October 27.

Alex Gibney and I will be doing a Q&A after the screening, moderated by the Washington Post’s Ceci Connolly.

Continue reading

The Health Care Lottery

Below, a guest-post by Nortin M. Hadler, M.D., Professor of Medicine and Microbiology/Immunology at UNC Chapel Hill’s School of Medicine.Dr. Hadler is also an Attending Rheumatologist at UNC Hospitals, and author of The Last Well Person: How to stay well despite the health care systemWorried Sick, A prescription for health in an overtreated America and Stabbed in the Back, Confronting back pain in an overtreated society.

I don’t buy lottery tickets. True, someone will win, and likely a mind boggling windfall. That someone may be one in a million, but someone will win. It is so unlikely to be that someone, maybe there’s a magical force at play, maybe a gambler’s gryphon or a good fairy. Many reasonable Americans must believe in the gambler’s gryphon. Some have premonitions, a sense that the gryphon will fend for them in the deepest reaches of improbability where the power ball hides. None of this is irrational behavior. All understand the probabilities and many get a kick out of the possibilities.

Continue reading

Mayo Clinic Family Medicine in Arrowhead Arizona Will No Longer Take Medicare Patients

The Mayo Clinic now has two family medicine clinics in Arizona. Beginning January 1, primary physicians at one of those clinics will no longer see Medicare patients unless they are able and willing to pay an annual $250 administrative fee, plus $175 to $400 per visit . They will also have to agree to“an appropriate number of visits each year, including physicals.

 The total annual costs for the physical and three office visits would be about $1500, according to  the letter that Mayo sent  to the 3,000 patients who receive care at the clinic. The letter also informs those patients that they will not be able to transfer their primary care to another Mayo facility.

Michael Yardley, chairman of public affairs of the Mayo Clinic in Arizona, said the changes are necessary because Medicare’s reimbursement rates for primary care are so low.  "It has been difficult for us to be able to sustain our own medical practice in a way to provide the best care to patients and for us," he told a local news outlet, youwestvalley.com.  “For some the $1500 annual fee- will be cost-prohibitive, and that’s why it’s so painful," Yardley acknowledged. "We have a list of physicians for them that are accepting new Medicare patients. We have done homework in that area, and we have customer service representatives for folks who we are encouraging them to talk to about it."

Continue reading

Should We Let Some States “Opt Out” of a Public Sector Insurance Option ?

There is now some talk of finding a compromise to the public option debate by including the public option in health reform legislation—and then letting individual states “opt out” leaving their citizens without the opportunity to sign up for a less expensive public plan modeled on Medicare, and letting private insurers set the market rules in those states. 

(Not long ago, the Washington Post reported that private insurers are already figuring out ways to “shun the sick,” despite health care reform. While they won’t be able to deny care because of pre-existing conditions, they can make their plans less attractive to cancer patients by including fewer oncologists in their networks.)

Continue reading

Why Aren’t We Winning The War On Cancer?

Below, a guest-post by HealthBeat reader Frederick L. Moolten, M.D. Professor of Medicine at the University of Pittsburgh Medical Center, he has devoted several decades of his career to cancer research, supported by the NIH and the VA.

We love wars.  Ever since our nation was forged in the heat of the American Revolution, we have celebrated victories in some (World War II – the “good war”), lamented the agony of others (the Civil War), and debated the merits of more recent ones, including Iraq and now Afghanistan.  Our combativeness extends into the realm of metaphor—hence the War On Drugs, the War On Poverty, and the War On Terror (only part metaphorical).  None of these has yet outlasted the War On Cancer, which we have been fighting for more than a century. Why have we not yet won?

Continue reading

Rethinking October’s Focus on Mammography

October is National Breast Cancer Awareness Month and the sea of pink has reached tidal-wave proportions. Every conceivable product from yogurt to running shoes to breakfast cereal now sports the ubiquitous pink ribbon. This month some NFL players will wear pink cleats, still more will don helmets festooned with pink ribbons, and legions of supporters are participating in walks, runs and bike rides to raise money for breast cancer causes. The collective spirit has been awakened; the American public wants progress on breast cancer!

But besides being a great marketing tool for selling “things,” what, ultimately, is the purpose of National Breast Cancer Awareness Month? The concept was introduced in 1985 by AstraZeneca, the giant international pharmaceutical company that makes the breast cancer drugs tamoxifen and Arimidex. The company’s aim was to promote regular mammograms as the most effective weapon in fighting breast cancer. It has since enlisted the support of such venerable groups as the American Cancer Society, the American College of Radiology, the National Cancer Institute and the Center for Disease Control, among others in this campaign.

Continue reading

The Health Care Debate Is Not “About Policy—or Values; It’s About Politics”

Over at the Hasting Center’s new “Values and Health Reform Connection,” blog Joanne Kenen’s candid post, “Honest Debate, and Candid Solutions” caught my eye. I recommend it to HealthBeat readers.  (Kenen writes The  New America Foundation’s “New Health Dialogue Blog.") Below, an excerpt:

“Liberty. Justice, Responsibility, Solidarity.

“These are some of the American Values highlighted in the Hastings Center’s report on Connecting American Values with Health Reform.

“Watching health reform unfold here in Washington, however, that ‘Connection’ is painfully elusive.  The debate is not a careful calibration of competing rights, values and obligations. It’s a political moshpit. Instead of values, we have vitriol.

“Outside of Washington, even extremely astute people ask me why we can’t fix a health care system that is inefficient, inequitable and downright inexplicable.

“I patiently explain that this fight is not purely about policy (or values). Health policy becomes a gritty proxy for politics.

“Values, or at least ideology – particularly about the size and reach of government – play a role in politics. But an awful lot of what passes for policy debate is trench warfare before the next election.  Look at the list of amendments proposed for any of the major bills – and ask yourself how many are meant to improve the health and well-being of the American people and the American economy, and how many are meant to score points, woo donors, placate interest groups and create a C-Span moment.” [my emphasis]

To read the rest of Kenen’s essay, click here.

Connecting American Values with American Health Care Reform

The Hastings Center, a nonpartisan bioethics research institute, recently asked me to write an essay to help launch their new group blog, The Values and Health Reform Connection. The website focuses on American values, and why they matter to health care reform.  Here is the link to the blog

Below, an excerpt from the piece that I wrote:

“While many speak of health care as an individual ‘right,’ I prefer to think of universal coverage as something that we, as a civilized nation, desire for all members of our society because we recognize each other as equally human, vulnerable, and in need of care.

Continue reading

Some Medicare Advantage Plans Do Provide Value—the HMOs

When I reported on the waste in Medicare Advantage plans not long ago, HealthBeat reader Don Grunt pointed out that not all MA plans are alike. He wrote: “I'm a Medicare Advantage product manager in Oregon where 45% of beneficiaries sign up for MA plans (highest in the country) because we offer good plans and the competitive market keeps us honest.  So I don't work in Miami or any of the wild west of MA plans.”

Oregon is one of those states that belongs to what I like to call “Canada South” (a region that includes part of the Northwest as well as the northern tip of New England–Vermont, New Hampshire and Maine). These are states where medicine seems less “money-driven,” and by and large, patients get better value for their health care dollars. In many of these states, care is more collaborative. It struck me that Don Grunt, who knows the MA system from the inside, was probably right.

I kept his remarks in mind when I wrote a piece for the Washington Post’s “HealthCare Rx” last week. (I am part of the “HealthCare Rx” standing panel, a group that spans a spectrum of opinion, ranging from Ezra Klein to Newt Gingrich. Each week, Rachel Saslow, the Rx editor, poses a question.  Last week’s query: “The Senate Finance Committee is debating a bill that would trim $113 billion from the privately-run Medicare Advantage plans over the next decade, a move that proponents say will bring its funding in line with traditional Medicare coverage. Do you think such a move will hurt beneficiaries?”

Continue reading